Drugs / CKD-506
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05238948 | Feb → Apr 2022 | — | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04204603 | Nov 2018 → Sep 2019 | rheumatoid arthritis | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CKD-506 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04204603 ↗ |
| Route | Oral | “Tablets for oral administration” NCT04204603 ↗ |